ArticleNature cancer2023

Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer.

Tizita Z Zeleke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.